Virtual Library

Start Your Search

Feng Chen

Author of

  • +

    P3.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 982)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.16-01 - A Multi-Omic Study Reveals BTG2 as a Reliable Prognostic Marker for Early-Stage Non-Small Cell Lung Cancer (ID 13586)

      12:00 - 13:30  |  Author(s): Feng Chen

      • Abstract
      • Slides


      Background: B-cell translocation gene 2 (BTG2), which functions as a tumor suppress gene, has been reported to be involved in several cancers. However, no study has focused on its role in lung cancer progression or prognosis. We aimed to investigate the role of BTG2 in early-stage non-small cell lung cancer (NSCLC) survival

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Patients and Methods: This study included 1,230 early-stage (I, II) surgically treated NSCLC patients with methylation and expression data from five international cohorts. We built a prognostic model based on BTG2 methylation. Then, we explored BTG2 expression and NSCLC survival in 3,038 cases, including the above-mentioned cohorts as well as 17 extended public datasets by meta-analysis. Further, we integrated the clinical information, expression, and methylation to build an integration model and evaluated its prediction ability using C-index.

      4c3880bb027f159e801041b1021e88e8 Result

      Results: Three risk CpG probes (cg01798157, cg06373167, cg23371584) were associated with overall survival. The prognostic model based on methylation could distinguish patient survival in the four cohorts [hazard ratio (HR) range, 1.51 to 2.21] and the independent validation set (HR = 1.85). In the expression analysis, BTG2 acted as a tumor-suppress gene in each cohort (HR range, 0.28 to 0.68). A meta-analysis showed high BTG2 expression was associated with better survival (HR = 0.61, 95%CI: 0.54-0.68). The three CpG probes were all negatively correlated with BTG2 expression. Further, the integration model based on BTG2 methylation, expression and clinical information showed a better prediction ability in the training set and validation set.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Conclusions: The methylation and integrated prognostic signatures based on BTG2 are stable and reliable biomarkers for early-stage NSCLC. They may have new applications for appropriate clinical adjuvant trials and personalized treatments in the future.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.